In 5/6 ETP-ALL xenografted mice with JAK–STAT pathway overactivation, monotherapy with ruxolitinib significantly decreased the number of peripheral and splenic blast counts.92 The remaining xenograft did not have increased JAK–STAT activation and was less responsive to ruxolitinib, with only a decrease in splenic blast count. This evidence concerns the gene SOAT1 and acute lymphoblastic leukemia.